A detailed history of Erste Asset Management Gmb H transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 54,000 shares of LYEL stock, worth $36,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,000
Holding current value
$36,180
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $61,019 - $101,520
54,000 New
54,000 $81.5 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $166M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.